These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 8504796)
1. Steady state pharmacokinetics of conventional versus controlled-release carbamazepine in patients with epilepsy. Bonneton J; Iliadis A; Genton P; Dravet C; Viallat D; Mesdjian E Epilepsy Res; 1993 Mar; 14(3):257-63. PubMed ID: 8504796 [TBL] [Abstract][Full Text] [Related]
2. Steady state pharmacokinetics of carbamazepine-phenobarbital interaction in patients with epilepsy. Sennoune S; Iliadis A; Bonneton J; Barra Y; Genton P; Mesdjian E Biopharm Drug Dispos; 1996 Mar; 17(2):155-64. PubMed ID: 8907722 [TBL] [Abstract][Full Text] [Related]
3. A comparison of the efficacy and tolerability of controlled-release carbamazepine with conventional carbamazepine. Dhalla Z; Bruni J; Sutton J Can J Neurol Sci; 1991 Feb; 18(1):66-8. PubMed ID: 2036618 [TBL] [Abstract][Full Text] [Related]
4. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. McKee PJ; Blacklaw J; Butler E; Gillham RA; Brodie MJ Br J Clin Pharmacol; 1991 Jul; 32(1):99-104. PubMed ID: 1888646 [TBL] [Abstract][Full Text] [Related]
5. [A practical study of the efficacy of a delayed-action preparation of carbamazepine (Tegretol CR 400) in the treatment of patients with partial epilepsy ]. Vojvodić NM; Sokić DV; Janković SM; Lević Z Srp Arh Celok Lek; 2002; 130(1-2):19-26. PubMed ID: 12073283 [TBL] [Abstract][Full Text] [Related]
6. Carbamazepine (CBZ) controlled release compared with conventional CBZ: a controlled study of attention and vigilance in children with epilepsy. Pieters MS; Jennekens-Schinkel A; Stijnen T; Edelbroek PM; Brouwer OF; Liauw L; Heyer A; Lanser JB; Peters AC Epilepsia; 1992; 33(6):1137-44. PubMed ID: 1464276 [TBL] [Abstract][Full Text] [Related]
7. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Powell G; Saunders M; Marson AG Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617 [TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329 [TBL] [Abstract][Full Text] [Related]
9. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects. Bareggi SR; Tata MR; Guizzaro A; Pirola R; Parisi A; Monza CG Int Clin Psychopharmacol; 1994; 9(1):9-16. PubMed ID: 8195585 [TBL] [Abstract][Full Text] [Related]
10. Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy. Lee BI; No SK; Yi SD; Lee HW; Kim OJ; Kim SH; Kim MK; Kim SE; Kim YS; Kim JM; Lee SJ; Shin DJ; Park SP; Kim YI; Heo K; Cho YW; Cho YJ; Kim YN Seizure; 2018 Feb; 55():17-24. PubMed ID: 29324401 [TBL] [Abstract][Full Text] [Related]
11. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. Carlsson KC; Hoem NO; Glauser T; Vinks AA Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311 [TBL] [Abstract][Full Text] [Related]
12. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Battino D; Croci D; Rossini A; Messina S; Mamoli D; Perucca E Epilepsia; 2003 Jul; 44(7):923-9. PubMed ID: 12823575 [TBL] [Abstract][Full Text] [Related]
13. Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Aldenkamp AP; Alpherts WC; Moerland MC; Ottevanger N; Van Parys JA Epilepsia; 1987; 28(5):507-14. PubMed ID: 3653052 [TBL] [Abstract][Full Text] [Related]
14. Carbamazepine metabolism in humans: effect of concurrent anticonvulsant therapy. Ramsay RE; McManus DQ; Guterman A; Briggle TV; Vazquez D; Perchalski R; Yost RA; Wong P Ther Drug Monit; 1990 May; 12(3):235-41. PubMed ID: 2112276 [TBL] [Abstract][Full Text] [Related]
16. The influence of polytherapy on the relationships between serum carbamazepine and its metabolites in epileptic children. Liu H; Delgado MR Epilepsy Res; 1994 Mar; 17(3):257-69. PubMed ID: 8013448 [TBL] [Abstract][Full Text] [Related]
17. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine. Bialer M; Arcavi L; Sussan S; Volosov A; Yacobi A; Moros D; Levitt B; Laor A Epilepsy Res; 1998 Nov; 32(3):371-8. PubMed ID: 9839777 [TBL] [Abstract][Full Text] [Related]
18. Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication. Svinarov DA; Pippenger CE Ther Drug Monit; 1996 Dec; 18(6):660-5. PubMed ID: 8946662 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients. Deleu D; Aarons L; Ahmed IA Eur J Clin Pharmacol; 2001 Jun; 57(3):243-8. PubMed ID: 11497340 [TBL] [Abstract][Full Text] [Related]
20. [The effect of antiepileptic drug therapy on antioxidant enzyme activity and serum lipid peroxidation in young patients with epilepsy]. Sołowiej E; Sobaniec W Neurol Neurochir Pol; 2003; 37(5):991-1003. PubMed ID: 15174247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]